Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
13.56
+1.16 (9.35%)
At close: Dec 5, 2025, 4:00 PM EST
13.16
-0.40 (-2.95%)
After-hours: Dec 5, 2025, 6:34 PM EST
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Aardvark Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.63, which forecasts a 125.88% increase in the stock price over the next year. The lowest target is $18 and the highest is $50.
Price Target: $30.63 (+125.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +32.74% | Nov 14, 2025 |
| BTIG | BTIG | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +91.74% | Nov 7, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +143.36% | Oct 1, 2025 |
| Stifel | Stifel | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +76.99% | Sep 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +194.99% | Sep 23, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
510.00K
EPS This Year
-3.01
from -5.15
EPS Next Year
-3.73
from -3.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 3.2M | ||||
| Avg | n/a | 510,000 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.82 | -2.09 | ||||
| Avg | -3.01 | -3.73 | ||||
| Low | -3.06 | -5.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.